Compare Vale SA (VALE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vale SA vs Viatris Inc — how do they compare? Vale SA trades at $13.5 (market cap $58.70B), while Viatris Inc trades at $17.4 (market cap $20.12B). The key difference: Vale SA is far larger — about 2.9× Viatris Inc's market cap, and Vale SA pays the higher dividend (8.75%). Which is the better fit depends on your goals — on Pluang, investors hold Vale SA for 109 Days and Viatris Inc for 57 Days on average.
| VALE | VTRS | |
|---|---|---|
Market Cap | $58.70B | $20.12B |
Volume | 45,073,516 | 7,543,511 |
Sector | Basic Materials | Health |
52-Week High | $17.82 | $18.27 |
52-Week Low | $10.75 | $9.74 |
Typical Hold Time | 109 Days | 57 Days |
Enterprise Value | $74.94B | $32.24B |
Dividend Yield | 8.75% | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VALE trades at $13.42, down 4.69% today amid broader sector weakness. The stock shows bearish technical signals with recent earnings misses and declining profit margins (5.11% net margin in 2025). Revenue has stabilized around $38-41B, but net income fell to $2.35B in 2025 from $18.8B in 2022. The company maintains strong cash flow generation ($8.8B operating cash flow) and recently declared a $0.40 dividend payable September 2026.
VALE faces headwinds from iron ore price volatility and rising costs, but base metals growth provides diversification. Analyst consensus is mixed with 32% buy ratings and a $16.21 price target suggesting 21% upside. Key risks include Brazilian regulatory exposure and cyclical commodity dependence. The current valuation (P/E 27.22) appears stretched given earnings compression.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue trends show a slight decline from $16.3B in 2022 to $14.3B in 2025, but net losses have widened significantly, reaching -$3.51B in 2025. Positive cash flow generation and a dividend payment scheduled for September 2026 highlight financial stability amid profitability challenges.
The outlook for VTRS is mixed; analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside, supported by strong cash flow and recent product approvals. However, persistent net losses, high P/E ratio of 236.2, and substantial long-term debt of $14.04B pose risks. Investors should weigh the potential for operational turnaround against ongoing profitability concerns and competitive pressures in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
